Stock Evaluator: Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. LXEO

$2.96 0.01 0.34%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,800,227
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Commentary & Analysis


Financial Summary

Share Statistics LXEO Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $245.5 $203.5 31%
Shares Out (Mil) 88.7 55.2 59%
Institutional Ownership 99.5% 93.3% 89%
Float (Mil) 50.5 40.4 46%
Beta 1.65 1.05 86%
Avg Daily Volume (000s) 5,141 569 92%
Price Change
(52-week)
(67.4%) 38.8% 14%
Growth LXEO Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (80.6%) (10.7%) 3%
EPS (5yr) 12.2% 15.4% 51
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (51.9%) (15.7%) 6%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 6 7
Current EPS ($0.354) ($1.338) ($1.481)
Month Ago EPS ($0.331) ($1.199) ($1.364)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.331) ($1.199) ($1.369)
Year/Year Chg (18.1%) (28.2%) (14.8%)
Financials LXEO Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($105) ($44) 11%
EPS (TTM) ($1.268) ($1.400) 18%
Operating Cash Flow (TTM) (Mil) ($87) ($35) 7%
Net Cash Flow (TTM) (Mil) $49 $-0 70%
Long-Term Debt (Q1) (Mil) $4 $4 23%
Enterprise Value (Q1) (Mil) $79 $142 20%
Valuation LXEO Industry
Median
Percentile
(All Stocks)
P/B 1.13 1.96 34%
P/E na 16.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios LXEO Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (54.3%) (47.0%) 10%
ROE (62.4%) (51.8%) 13%
Liabilities to Assets 11.2% 29.6% 7%
F-Score 4 3 33%

Passing Stock Screens

As of 11/20/2026, from a list of 60 stock screening strategies, LXEO meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors